Stockscreener 앱 받기
0.1899
1.20%
-0.0023
시간 외 거래:
.20
0.0101
+5.32%
전일 마감가:
$0.1922
열려 있는:
$0.199
하루 거래량:
286.70K
Relative Volume:
0.43
시가총액:
$3.67M
수익:
$420.00K
순이익/손실:
$-19.65M
주가수익비율:
-0.00137
EPS:
-138.243
순현금흐름:
$-26.08M
1주 성능:
-35.40%
1개월 성능:
-63.59%
6개월 성능:
-98.01%
1년 성능:
-99.72%
1일 변동 폭
$0.1821
$0.1997
1주일 범위
$0.1146
$0.298
52주 변동 폭
$0.1146
$95.50
칼라 파마슈티컬스 Stock (KALA) Company Profile
명칭
Kala Bio Inc
전화
781-996-5252
주소
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.1899 | 3.67M | 420.00K | -19.65M | -26.08M | -138.24 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
칼라 파마슈티컬스 Stock (KALA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-09-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | 개시 | Mizuho | Outperform |
| 2025-07-11 | 개시 | Ladenburg Thalmann | Buy |
| 2022-03-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-09-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-07-23 | 개시 | Northland Capital | Outperform |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-27 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-09 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 개시 | Jefferies | Buy |
모두보기
칼라 파마슈티컬스 주식(KALA)의 최신 뉴스
KALA Bio Inc.: KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception - FinanzNachrichten.de
A telehealth platform has generated over $48 million in sales since 2023. KALA Bio may buy it. - Stock Titan
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products - Yahoo Finance
Kala Pharmaceuticals Inc (NYSE: KALA) Share Price, KALA Stock News, KALA Share Price & Updates - kalkine.ca
Kala Pharmaceuticals Inc (NYSE: KALA) Share Price, KALA Stock News, KALA Share Price & Updates - Kalkine
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team - Yahoo Finance
Reverse stock split heads to a vote at KALA BIO (NASDAQ: KALA) - Stock Titan
Kala Bio announces annual shareholder meeting - Bitget
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com India
Kala Bio signs exclusive US distribution deal with Virotek for ophthalmology genetic testing - Investing.com UK
Kala Bio Secures Exclusive Ophthalmic Genetic Testing Deal - TipRanks
Kala Bio Secures 5-Year Exclusive U.S. Distribution for Ophthalmic Genetic Testing With Virotek - tradingview.com
KALA BIO, Inc. Enters Exclusive Distribution And Reseller Agreement With Virotek, Inc - marketscreener.com
KALA BIO (NASDAQ: KALA) Announces November 3, 2026 Annual Meeting and September 19 Proposal Deadline - Kalkine Media
KALA BIO Updates Annual Meeting and Proposal Deadlines - TipRanks
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - Stock Titan
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com Nigeria
KALA Stock Update: Exclusive U.S. Distribution Deal with Virotek Highlights Growth Challenges - GuruFocus
Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests - Yahoo Finance
Kala Bio secures exclusive U.S. rights to Virotek genetic tests By Investing.com - Investing.com South Africa
Kala Bio secures exclusive U.S. rights to Virotek genetic tests - Investing.com
Kala Bio and Virotek Finalize Definitive Agreement - GlobeNewswire
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - Yahoo Finance
Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership - finance.yahoo.com
Kala Bio, Virotek enters LOI for distribution agreement - TipRanks
KALA Bio (KALA) Signs Exclusive Distribution LOI with Virotek, F - GuruFocus
Kala Bio, Virotek Outline Exclusive U.S. Genetic Testing | KALA Stock News - Stock Titan
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program - Yahoo Finance
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - The Globe and Mail
KALA BIO Faces Nasdaq Delisting Risk on Minimum Bid Price Failure - Minichart
KALA BIO Faces Nasdaq Listing Compliance Uncertainty - TipRanks
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Aimwell Bio pays in shares, not cash, for Trustr technology and begins naming contributors - Stock Titan
KALA (KALA) Close: Ends Down by 2.39% at $0.82 at the Close; Boundary Watch: Traders Can Monitor the $0.78-$0.86 Range in the Latest ReadingLow Vol ETF - vinanet.vn
Kairos Pharma Announces 1-for-7 Reverse Stock Split - Yahoo Finance
KALA (KALA) Technicals: Moves 6.67% Down to $0.84; Technical Setup: the Supplied Trading Band Runs From $0.80 to $0.88 at the CloseProtective Put - vinanet.vn
KALA BIO Q2 Net Loss Narrows to $1.58 Million Amid Sharp Spending Cuts - Minichart
KALA BIO: Q2 Earnings Snapshot - AOL.com
KALA BIO: Q2 Earnings Snapshot - KTVB
KALA BIO, Inc. Q2 2026: Net loss $(1.58M), EPS $(21.32) — 10-Q Summary - TradingView
KALA: Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable - TradingView
KALA BIO (KALA) pivots to biotech AI with $229K on hand - Stock Titan
KALA (KALA) Session: Retreats 0.97% to $0.89; Next Session: Price Remains Between $0.85 Support and $0.93 Resistance in the Latest ReadingRTH Profile - vinanet.vn
K Wave Media Ltd. Announces Pricing of $1.0 Million Registered Direct Offering - Yahoo Finance
KALA Q4 2025 Earnings: Loss Narrows to -33.5 Per Share, Beating Estimates by 54.38Performance Review - vinanet.vn
KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks
KALA BIO (KALA) delays June 30, 2026 Form 10-Q to finalize liquidity analysis - Stock Titan
KALA Q4 2025 Earnings: Narrower-Than-Expected Loss Delivers a 54.38 EPS SurpriseDividend Growth Analysis - vinanet.vn
칼라 파마슈티컬스 (KALA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
칼라 파마슈티컬스 주식 (KALA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Howard B Rosen | Director |
Mar 12 '26 |
Proposed Sale |
0.29 |
13,576 |
3,975 |
0 |
| CHARLES D MYERS | Director |
Mar 12 '26 |
Proposed Sale |
0.31 |
9,112 |
2,858 |
0 |
| MARY REUMUTH | Officer |
Oct 23 '25 |
Proposed Sale |
0.82 |
967 |
793 |
0 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| MARK IWICKI | Director |
Oct 23 '25 |
Proposed Sale |
0.81 |
154,894 |
125,185 |
0 |
| Iwicki Mark T | Director |
Oct 23 '25 |
Sale |
0.81 |
154,894 |
125,464 |
103,540 |
| TODD M BAZEMORE | Officer |
Oct 22 '25 |
Proposed Sale |
0.83 |
47,768 |
39,686 |
0 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
4.22%
자본화:
|
볼륨(24시간):